

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



Pfizer and ASKA Pharmaceutical Announce Co-promotion of RSV Vaccine "ABRYSVO® Intramuscular Injection"

TOKYO, March 6, 2026 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), and Pfizer Japan Inc. (Head Office: Shibuya-ku, Tokyo/ President and Representative Director: Hiroo Igarashi), today announced that they will begin co-promotion of the Respiratory Syncytial Virus (RSV) vaccine "ABRYSVO® intramuscular injection" (generic name: Recombinant Respiratory Syncytial Virus Vaccine, hereinafter "ABRYSVO"), in Japan starting April 1, 2026. Details are shown in the attachment..

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp

Press release

March 6, 2026
Pfizer Japan Inc.
ASKA Pharmaceutical Co., Ltd.

Pfizer and ASKA Pharmaceutical Announce Co-promotion of RSV Vaccine "ABRYSVO® intramuscular Injection"

Pfizer Japan Inc. (Head Office: Shibuya-ku, Tokyo/ President and Representative Director: Hiroo Igarashi), and ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter "ASKA Pharmaceutical") today announced that they will begin co-promotion of the Respiratory Syncytial Virus (RSV) vaccine "ABRYSVO® intramuscular injection" (generic name: Recombinant Respiratory Syncytial Virus Vaccine, hereinafter "ABRYSVO"), in Japan starting April 1, 2026.

The overview is as follows:

- Purpose of collaboration: To quickly and widely disseminate information on the proper use of ABRYSVO in the maternal immunization applications
- Division of roles: Providing mutually agreed upon information on appropriate use to medical institutions in Japan
(Pfizer will continue to be responsible for development, manufacturing, distribution, sales, etc. as before.)

ABRYSVO is the first RSV vaccine given during pregnancy as maternal immunization in Japan, and it is expected that neutralizing antibodies against RSV induced in the vaccinated mother will transfer to the fetus, thereby protecting newborns and infants after birth from RSV infection.

Through this co-promotion, Pfizer, the manufacturer and distributor of this vaccine, and ASKA Pharmaceutical, which has strengths in the field of obstetrics and gynecology, will leverage their respective expertise and networks within the healthcare facilities to further strengthen the provision of information on this new preventive approach for RSV, the maternal immunization, and the promotion of its appropriate use.

RSV infection is one of the major causes of lower respiratory tract diseases such as bronchiolitis and pneumonia in infants, and is known to be at a particularly high risk of developing severe illness in infants shortly after birth. Through this initiative, the two companies aim to contribute to seamless infection prevention from pregnancy through to infancy.

Furthermore, at the Subcommittee on Immunization and Vaccines, Health Science Council held on February 12, 2026, it was agreed that this vaccine would be designated for use in the routine vaccination schedule starting April 2026 for the prevention of RSV infection in children (Category A routine vaccination).

ABRYSVO (Maternal Immunization) Product Overview

*Excluding matters related to the prevention of infection caused by the RSV in adults aged 60 years of age and older

Trade name	ABRYSVO® intramuscular injection
Generic name	Recombinant Respiratory Syncytial Virus Vaccine
Indication	Prevention of lower respiratory tract disease caused by respiratory syncytial virus in newborns and infants through active immunization of pregnant women
Dosage and Administration	Reconstitute the antigen with the entire volume of the provided diluent, and administer as a single 0.5 mL dose of intramuscular injection to pregnant women between 24 and 36 weeks of gestation.

Press release

Date of approval for manufacturing and sales	January 18, 2024
Release date	May 31, 2024
Manufacturer	Pfizer Japan Inc.

<Reference information>

About RSV infection

RSV is widespread all over the world, with nearly all children experiencing infection by the age of two. It is the main cause of bronchiolitis and viral pneumonia in infants, and infection is said to be particularly severe in children under 6 months of age¹. In Japan, it is estimated that approximately 120,000 to 140,000 infants under the age of two are diagnosed with RSV infection each year, and about one-quarter of these require hospitalization². Hospitalization of infants under two years of age due to RSV infection often occurs without any underlying medical conditions, and the incidence peaks at one to two months of age, so preventive measures are necessary from early in life. In Japan, RSV infection is classified as a Category 5 infectious disease under the Infectious Diseases Control Law, and its epidemiological status is being monitored through reports from designated pediatric medical institutions.

ABRYSVO® intramuscular injection (Recombinant Respiratory Syncytial Virus Vaccine)

The development of ABRYSVO® intramuscular injection is based on fundamental research, including studies on the pre-fusion F protein crystal structure conducted by the U.S. National Institutes of Health (NIH). The F protein is a membrane protein that RSV uses to enter human cells. This study suggests that a vaccine based on the pre-fusion F protein of RSV may have the potential to prevent RSV infection. Building on this NIH discovery, Pfizer evaluated multiple pre-fusion F protein structures and identified vaccine antigens that elicited strong antiviral immune responses in nonclinical studies. This vaccine is bivalent, containing recombinant F proteins from both RSV A and RSV B. In the United States, the drug received breakthrough therapy designation in 2022, and in August 2023, it received approval from the U.S. Food and Drug Administration (FDA) for its maternal immunization indication. Additionally, in September of the same year, it received a recommendation from the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC). In addition, it was approved in the EU by the European Medicines Agency (EMA) in August 2023.

<Source>

1. Japan Institute for Health Security, The Infectious Disease Information Website (IASR Vol. 46 pp113-115: June 2025 issue)
<https://id-info.jihs.go.jp/surveillance/iasr/pathogens/vol46/544/544t.html>
2. Kobayashi Y, Togo K, Agosti Y, et al. Epidemiology of respiratory syncytial virus in Japan: A nationwide claims database analysis. *Pediatr Int.* 2022 Jan;64(1): e14957.
3. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryuu/kenkou/kekkaku-kansenshou/kekkaku-kansenshou11/01.html#ist07

Press release

About Pfizer: Breakthroughs that change patients' lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit our website and official social media accounts. www.pfizer.com (Pfizer head office , USA) www.pfizer.co.jp, [Instagram](#), [X](#) (Japanese company)

About ASKA Pharmaceutical: A leading company in Women's Healthcare

ASKA Pharmaceutical operates under the corporate philosophy of "Contribute toward the improvement of people's health and progress in medicine through the development of innovative products," and focuses on internal medicine (gastroenterology, thyroid), obstetrics and gynecology, and urology. The company is committed to becoming a competitive specialty pharma company by centering its business on the development of innovative drugs. We will solidify our position as a competitive specialty pharma company and, based on our contributions through pharmaceuticals, contribute to people's health by responding to changing social needs. For more details, please visit its website. <https://www.aska-pharma.co.jp/english/>

<Inquiries regarding this press release>

Communications, Pfizer Japan Inc.

JPN-ExtComms_inquiry1@pfizer.com

ASKA Pharmaceutical Co., Ltd.

Corporate Planning Department

TEL: +81-3-5484-8366 - kouhou@aska-pharma.co.jp